Cleveland State University

Technology Transfer Office

Available Technologies - Abstract


Thrombin Generation Inhibitors.

Short Description Methods and medicines for inhibiting blood coagulations.
Abstract Existing blood anticoagulants produce a number of deleterious side effects. For example, heparin, warfarins, and thrombolytic agents all can cause bleeding. The present invention has discovered that certain peptides derived from the region comprising amino acids 307 to 356 of the human blood coagulation factor Va exhibit excellent blood coagulation properties with little or no adverse side effects.
Inventor(s) Dr. Michael Kalafatis, Ph.D. Professor, Department of Chemistry.
Commercial Applications
  • Novel therapeutic blood anticoagulation drug.
  • Processes for reducing and preventing unwanted clotting of blood.
  • Unlike existing blood anticoagulants, the present invention targets single clotting factors such that side effects resulting from nonspecific action of the drug are eliminated.
  • Superior efficacy and safety profiles since thromboses would be inhibited without bleeding as a side effect.
IP Information 7,074,892
Related IP


Status Available
engaged learning
  • Partners
Campus Location
Parker Hannifin Hall, 214
2258 Euclid Avenue
Cleveland, OH 44115
Phone: 216.687.5108
This site contains files that require the free Adobe Reader to view.